Allist(SH:688578) Xin Lang Zheng Quan·2025-10-31 23:39Core Viewpoint - Ailis, a leading player in the domestic innovative drug sector, focuses on the research, production, and sales of innovative drugs, with its self-developed drug, Fumetinib, showcasing significant technological advantages [1] Group 1: Business Performance - For Q3 2025, Ailis reported revenue of 3.733 billion yuan, ranking 20th out of 110 in the industry, with the top company, East China Pharmaceutical, generating 32.664 billion yuan [2] - The net profit for the same period was 1.616 billion yuan, placing Ailis 7th in the industry, while the leading company, Heng Rui Medicine, reported a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - Ailis's debt-to-asset ratio stood at 10.48% in Q3 2025, slightly down from 10.49% year-on-year, significantly lower than the industry average of 35.26% [3] - The gross profit margin for Q3 2025 was 96.79%, an increase from 95.80% year-on-year, and well above the industry average of 57.17% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 46.82% to 19,100, while the average number of circulating A-shares held per shareholder decreased by 31.89% to 23,600 [5] Group 4: Executive Compensation - The chairman, Du Jinhao, received a salary of 4.9511 million yuan in 2024, an increase of 1.4204 million yuan from 2023 [4] Group 5: Analyst Ratings and Projections - Haitong International maintains an "outperform the market" rating for Ailis, projecting net profits of 1.929 billion yuan, 2.198 billion yuan, and 2.550 billion yuan for 2025-2027, with respective growth rates of 34.9%, 13.9%, and 16.0% [6] - Yongxing Securities holds a "buy" rating, forecasting revenues of approximately 5.02 billion yuan, 6.02 billion yuan, and 7.04 billion yuan for 2025-2027, with year-on-year growth rates of 41.0%, 19.9%, and 17.0% [7]